Chemical composition and oral sub-chronic safety of Algerian propolis with in silico targeting of Keap1-Nrf2 and mitochondrial proteins Authors: Widad Kebsa, Hassiba Rouibah, Samia Belahcene, Tomilola Victor Akingbade, Haruna Isiyaku Umar, Mesbah Lahouel, Rana M Aldossari, Vidya Devanathadesikan Seshadri, Sadaf Farooqui, Sherouk Hussein Sweilam Published: 2026 ABSTRACT AbstractAlgerian propolis has shown promising biological activities, but data on its safety profile remain limited. This study investigated the phytochemical composition and antioxidant activity of an ethanolic extract of Algerian propolis (EEP), as well as its sub-chronic toxicity at an oral dose of 100 mg/kg/day for 30 days in rats. EEP exhibited high levels of total polyphenols and flavonoids with low contents of hydrolysable and condensed tannins. GC–MS analysis identified naringenin (17.48%), pinocembrin (15.62%), 3-(acetylmethyl)-β-pinene (8.23%), 3(Z)-cembrene A (6.36%) and totarol (5.78%) as major constituents. In vitro, EEP effectively scavenged superoxide anion (O2-), DPPH- and H2O2 and showed strong reducing power in the FRAP assay. In vivo, EEP limited superoxide anion generation, inhibited mitochondrial permeability transition pore (mPTP) opening and protected against mitochondrial swelling and apoptosis. It also preserved redox homeostasis by decreasing malondialdehyde (MDA) levels and increasing superoxide dismutase (SOD) and catalase (CAT) activities, as well as glutathione (GSH) content. Histopathological examination revealed normal liver and kidney architecture comparable to controls. In silico analyses indicated favorable pharmacokinetic properties and negative predicted organ toxicity for the main constituents. Molecular docking showed strong binding affinities toward Keap1–Nrf2 and mitochondrial targets, including the bc1 complex, Mn-SOD and cyclophilin D. Overall, these findings support the oral sub-chronic safety profile and mitochondria-protective antioxidant potential of Algerian propolis.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-58242-2.Keywords: Propolis, GC-MS analysis, Sub-chronic toxicity, Keap1-Nrf2, bc1 complex, Cyclophilin DSubject terms: Biochemistry, Drug discovery, Plant sciences Introduction Propolis is a complex, resinous substance produced by bees, composed mainly of wax, sugars, and plant secretions. Its medicinal properties have been widely studied1. The phytochemical composition of propolis is influenced by a myriad of environmental and geographical determinants in addition to its botanical source, which complicates efforts to achieve standardization2. More than 800 distinct molecules have been identified3,4, with flavonoids, aromatic acids, terpenes, and phenolic compounds acknowledged as the primary components accountable for its pharmacological effects5. Propolis has been used by humans since ancient times, even before honey, and today it is generally marketed as a dietary supplement. In contrast to numerous other natural remedies, propolis is backed by extensive scientific evidence highlighting its antibacterial, antioxidant, anti-inflammatory, antidiabetic, and anticancer properties, among others6,7. In Algerian traditional medicine, propolis is widely used—especially in northwestern regions—mainly as decoctions, pastes, or ethanolic tinctures often mixed with honey to treat digestive, liver, and kidney disorders8,9. According to long-standing ethnomedical beliefs, these formulations are traditionally believed to purify the blood and stimulate liver and kidney functions. Contemporary pharmacological investigations have provided scientific validation for many of these traditional uses7,10. In terms of safety, propolis generally exhibits low acute toxicity, with reported mouse LD50 values from 2000 to 7300 mg/kg and no adverse effects at oral doses reaching 4000 mg/kg/day11. However, adverse reactions have been documented in hypersensitive individuals, including a case of acute renal failure following Brazilian propolis supplementation during cancer therapy12. Algerian propolis has demonstrated hepatoprotective and antioxidant activity13–15. Its sub-chronic toxicity remains unexplored, highlighting the need for further investigation of its long-term effects on the antioxidant–prooxidant balance. Mitochondria are widely documented as the key contributors to reactive oxygen species (ROS) production, which arise as byproducts of the electron transport chain (ETC) during oxidative phosphorylation16. ROS formation, particularly at complex I and complex III (ubiquinol–cytochrome c reductase or bc1-complex), leads to superoxide (O₂⁻) and hydrogen peroxide (H₂O₂) generation. In the absence of effective neutralization by antioxidant mechanisms, ROS induce lipid peroxidation, protein oxidation, and mutations within mitochondrial DNA, impairing mitochondrial function and perpetuating a vicious cycle of oxidative stress. Other cellular sources, such as NADPH oxidases (NOX), also contribute to ROS production17. Notably, the strategic partial inhibition of mitochondrial complexes I or III has been proposed as a promising therapeutic approach to attenuate mitochondrial oxidative stress and limit cellular injury. The mitochondrial permeability transition pore (mPTP), situated in the inner mitochondrial membrane, represents another critical contributor to oxidative stress. Normally closed, it opens under toxic stimulation driven by ROS, leading to matrix swelling, Ca²⁺ release, and activation of proteases, phosphatases, and nucleases, which ultimately trigger apoptotic and necrotic18. Cyclophilin D (CypD), as an inhibitor of mPTP opening, modulates both oxidative stress and apoptosis. While CypD is widely recognized as a positive regulator, no clinically safe and effective inhibitor has yet been developed, largely due to toxicity and poor pharmacokinetics19. Consequently, CypD remains a promising target for novel therapies, and safe natural substances are currently under investigation. Furthermore, nuclear factor erythroid 2-related factor 2 (Nrf2) is the main transcription factor regulating oxidative stress. Normally sequestered in the cytoplasm by Keap1, Nrf2 is released under oxidative conditions, translocates to the nucleus, and subsequently binds to antioxidant response elements (AREs), thereby activating genes encoding superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Beyond this canonical role, Nrf2 also contributes to mitochondrial biogenesis and protection, particularly through PGC-1α activation, which helps preserve mitochondrial function and limit oxidative damage20,21. Consequently, Nrf2 is recognized as an important therapeutic target for disorders associated with oxidative stress. This study investigates the chemical composition, antioxidant potential, and sub-chronic toxicity of Algerian propolis, with a particular focus on mitochondrial oxidative stress. The pharmacokinetic profile and drug-likeness of the identified compounds were also evaluated using molecular docking, followed by virtual screening against antioxidant and antiapoptotic targets, including mitochondrial Keap1–Nrf2, ubiquinol–cytochrome c reductase, and cyclophilin D. Materials and methods Phytochemical study Collection and extraction of propolis Propolis was collected from the Kaous beekeeping cooperative in Jijel, Algeria (36° 46′ 13″ north, 5° 48′ 49″ east), by scraping the hive frames and walls in September 2024. Upon receipt, the samples were promptly stored at 4 °C in light-protected, non-transparent containers to preserve their stability until analysis. Raw propolis was first ground and washed twice with ethanol to eliminate debris. The material was subsequently macerated in 95% ethanol (plant-to-solvent ratio 1:10, w/v)) for two weeks, then filtered and evaporated at 40 °C, with rotations of 95 rpm in vacuum as previously described by Kebsa et al.14. The extraction yield (EY) is expressed as a percentage of the weight of the obtained dried extract relative to the initial dried matter of the sample used for extraction. Assessment of the total phenolic and flavonoid contents Total phenolic (TP) quantification was conducted using Singleton’s method as described in22. 125 µL of diluted EEP was combined with 0.5 mL of deionized water and 125 µL of Folin–Ciocalteu reagent. After a 6mn reaction period, 1.25 mL of NaCO3 (7%) was added, and the mixture volume was brought up to 3 mL. The sample was then incubated at 25 °C for 90 mn before measuring absorbance at 760 nm. The results were quantified by referencing a gallic acid calibration curve and are expressed as mg of gallic acid equivalents per g of extract (mg GAE/g). The quantification of total flavonoids (TF) was carried out as described by Dewanto et al.22. 50 µL of diluted (EEP) or Quercetin were mixed with 75 µL of NaNO2 5% solution. After a 6mn reaction time, 150 µL of AlCl3 10% was added, followed by 500 µL of 1 M NaOH. After dilution to 2.5 mL with distilled water, the absorbance was measured at 510 nm. Total flavonoid content was conveyed as milligrams of quercetin equivalents per gram of EEP (mg QE/g). Determination of hydrolysable tannins (HT) and condensed tannins (CT) HT was quantified using a modified procedure of the Mole and Waterman protocol23. EEP (0.2 g) was extracted in methanol for 18 h and filtered. The filtrate was mixed with ferric chloride in hydrochloric acid, incubated for 15 min, and the absorbance was taken at 660 nm. HT content (%) was calculated as HT (%) = (A × M × V) / (ε × P), Where: A = absorbance; M = (300 g/mol); V = sample’s volume; ε = molar extinction coefficient of gallic acid (2169 L/mol/cm); P = weight of the sample. CT was measured following the protocol of Swain and Hillis24. 1mL of EEP was added to 2 mL of vanillin (1%). After 15 min incubation, absorbance (A) was recorded at 500 nm. CT content (%) was calculated as CT (%) = (5.2 × 10⁻² × A × V) / P; V and P represent volume and weight of the sample. Gas chromatography–mass spectrometry (GC–MS) analysis The chemical composition of EEP was assessed by a Shimadzu QP2010 GC–MS system with a SE30 column (0.25 × 25 mm). Helium served as the carrier gas at 1.5 mL/min, 20:0 split ratio. Ionization by electron impact was performed at 70 eV, scanning from 40 to 450 m/z. The compound’s identification was carried out using its retention times and spectral comparison with the NIST05 2010 library, while relative abundances were calculated from peak areas. In vitro antioxidant activity DPPH free radical scavenging assay The DPPH test was performed according to the Brands et al. method25. EEP samples (1 mL), from (0–200 µg/mL) were added to 0.5 mL of DPPH (0.2 mM). Absorbance was then measured at 517 nm after a 30-minute incubation time. Radical scavenging rate was determined as [(A₀ – A₁) / A₀] × 100, where A₀ and A₁ denote the absorbance of the control and the sample, respectively. Scavenging capacity towards hydrogen peroxide (H2O2) The H₂O₂ scavenging activity of EEP was assessed following the Shah et al. method26. Various concentrations of EEP or Gallic acid (0–200 µg/mL) were added to 750 µL of H₂O₂ (10mM). Absorbance was recorded at 240 nm after 30 min of incubation, and scavenging activity (%) was calculated as previously described for the DPPH assay. Ferric-reducing antioxidant power (FRAP) The Ferric-reducing Antioxidant Power of EEP was determined following Sikder et al.27. 100 µL of EEP or gallic acid (0–200 µg/mL) was added to 2.5 mL of K3Fe(CN)6 (1%) and 2.5 mL of phosphate buffer (pH 6.6). After 20 min of incubation at 50 °C, 2.5 mL of trichloroacetic acid (TCA, 10%) was added, and the mixture was centrifuged at 3000 g for 10 min. 2.5 mL of the supernatant was combined with 2.5 mL of distilled water and 0.5 mL of FeCl3 (0.1%). Absorbance was measured at 700 nm, and the reducing power was then calculated. Superoxide anion scavenging assay The scavenging activity of (O₂⁻) radical was evaluated as described by Pan et al.28. 1mL of EEP or gallic acid (0–200 µg/mL) was added to 1,8 mL Tris-HCl buffer (50 mM, pH 8.2) and incubated at 25 °C for 10 mn. Then, 100 µL of pyrogallol (10 mM) was added, and absorbance at 320 nm was recorded over 4 mn. Scavenging effect (%) was calculated from the difference in oxidation rate slopes between the sample and control. Sub-chronic toxicity study Animals Male Wistar albino rats (~ 180 g) procured from the Pasteur Institute (Algeria) were housed under well-ordered conditions (25 ± 2 °C, 12 h light/dark cycle) with ad libitum access to regular feed and drinking water. Rats were allowed a 7-days acclimation period to laboratory conditions before the experiments. All experimental assays in this study were performed based on the internationally accepted protocols and ethics for laboratory animal care and use, as approved by the committee of the Algerian association of sciences in animal experimentation (N°. 8808/1988), associated with veterinary medical activities and animal health protection (N° JORA:004/1988). Experimental design For the sub-chronic toxicity assessment (OECD 407), rats were randomly assigned to two groups (n = 10 per group). Group 1 served as the control and received 1 mL/day of distilled water orally for 30 consecutive days. Group 2 received 1 mL/day of EEP at a dose of 100 mg/kg orally for the same duration. This dosage was chosen based on both previously published studies and our own prior work, in which similar doses demonstrated significant biological activity without inducing observable toxicity in comparable in vivo models13,15,29,30. At the end of the treatment period, body weights were recorded and blood samples were collected for biochemical analyses. After deep anesthesia was achieved with isoflurane, euthanasia was ensured by bilateral thoracotomy, in which the thoracic cavity was opened on both sides to collapse the lungs and abolish cardiac function, in accordance with institutional and international guidelines. Liver and kidney tissues were rapidly excised. Portions of each tissue were fixed in 10% neutral buffered formalin for histopathological examination, and the remaining samples were used for oxidative stress analyses. Body and relative organ weight (ROW) Organs were carefully excised, gently rinsed to remove residual blood, and weighed immediately. Relative organ weight (ROW) was calculated by normalizing organ weight to the corresponding body weight and expressed as a percentage. ROW (%) = organ weight (g)/body weight of animal (g) x 100. Biochemical assessment of hepato-renal markers Serum was obtained by centrifugation at 3000 g for 10 min and stored at − 20 °C until analysis. Serum levels of alanine aminotransferase EC2.6.1.2 (ALAT), aspartate aminotransferase EC2.6.1.1 (ASAT), lactate dehydrogenase EC 1.1.1.27 (LDH), and protein contents (PROT), which are indices for liver function, creatinine and blood urea nitrogen (BUN) for renal function were determined. All assays were performed using colorimetric methods according to the manufacturer’s instructions (Spinreact kits, Girona, Spain). Isolation of mitochondria and cytosolic fraction Mitochondria were isolated from liver and kidney homogenates by differential centrifugation according to the method of Rustin et al.31. Mitochondrial suspension was used for the measurement of superoxide anion production and swelling. Then, the mitochondrial matrix was prepared by successive freeze-thaw cycles and homogenization. Following centrifugation at 10,000 × g for 10 min32, the supernatant was carefully harvested for subsequent quantification of mitochondrial oxidative stress biomarkers. Cytosolic fractions were prepared as described by Sanmugapriya and Venkataraman33. Tissues were rinsed and homogenized in cold KH2PO4 buffer (0.15 M, pH 7.4) with 1.17% KCl (1:3 w/v) and centrifuged at 2000 rpm, 4 °C for 15 min to remove debris. The supernatant was further centrifuged at 10,000 rpm, 4 °C for 45 min. The final supernatants were used for cytosolic parameter assays. Mitochondrial superoxide anion (O₂⁻) production and mitochondrial permeability transition pore (mPTP) assays Superoxide anion formation was assessed through the reduction of nitro blue tetrazolium (NBT) into its monoformazan derivative, which absorbs at 560 nm, following the procedure reported by Zini and collaborators34. The reaction mixture was composed of mitochondria (0.2 mg/mL), cyclosporin A (1 µM), and NBT (100 µM) in 1.2 mL of a respiration buffer containing 250 mM sucrose and 5mM KH2PO4, pH 7.2. Rotenone was then added at a final concentration of 2 µM. Superoxide generation was triggered by supplying the system with succinate (6 mM). MPTP opening was assessed by monitoring mitochondrial swelling spectrophotometrically at 540 nm, according to the method of35. A decrease in absorbance indicates increased mitochondrial permeability and swelling. Assessment of oxidative stress markers Cytosolic and mitochondrial malondialdehyde (MDA) levels were measured following the protocol established by Ohkawa et al.36 and Zini et al.34 respectively. Glutathione (GSH) levels were determined spectrophotometrically using 5,5-dithiobis-2-nitrobenzoic acid (DTNB) as described in37. The method is based on the formation of a yellow-colored product upon reaction of DTNB with sulfhydryl groups. Absorbance was recorded at 412 nm. Total GSH concentration was calculated from a standard curve and expressed in µmol/g tissue. Catalase enzymatic activity was determined by monitoring the decomposition of hydrogen peroxide at 240 nm, following the method of Clairborne38. SOD activity was determined according to the method of Beauchamp and Fridovich39. The assay is based on the inhibition of NBT reduction by superoxide radicals generated under illumination. Enzymatic activities were expressed in IU/mg protein. Liver and kidney histology Liver and kidney tissues were fixed in 10% neutral buffered formalin, dehydrated through graded ethanol, cleared in xylene, and embedded in paraffin. Section (5 μm) were mounted on glass slides and stained with hematoxylin and eosin (H&E) according to standard histological procedures. Histopathological examinations and image acquisition were performed using an Optika B-190 TB light microscope equipped with a digital camera at magnifications of ×100 and ×200. In silico study ADME-Toxicity and drug likeness prediction In order to predict the pharmacokinetic and pharmacodynamic profiles of the compounds, an in silico assessment of their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties was conducted. Concurrently, the drug-likeness of the compounds was evaluated. These analyses were performed using the ADMET-AI web server (https://admet.ai.greenstonebio.com, accessed on May 2nd, 2026) and the SwissADME server (http://www.swissadme.ch, accessed on Jun 10th, 2025)40. Molecular docking Target preparation The 3D structures of Cyclophilin D (5CCS.pdb), Ubiquinol-cytochrome c reductase (bc1 complex (5XTE.pdb), Keap1-Nrf2 (6UF0.pdb), and Mitochondrial Superoxide dismutase (Mn-SOD) (5VF9.pdb) were sourced from the RCSB Protein Data Bank (https://www.rcsb.org/, accessed on Jun 15th, 2025) and provided in PDB format with a crystallographic resolution of 2.10 Å, 3.40 Å, 2.68 Å, 1.82 Å, respectively. Target preparation was conducted using BIOVIA Discovery Studio (version 20.1) and involved the systematic removal of crystallographic water molecules and non-essential bound co-factors. The potential binding cavities and active site coordinates for each target were subsequently identified and mapped using BIOVIA Discovery Studio (version 20.1), ensuring that docking simulations were targeted toward biologically relevant pockets. Ligands preparation Chemical, structural details, and canonical SMILES of the compounds were obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The SwissAdme server was employed to screen the compounds for Drug likeness properties40. The 2D structures were initially downloaded in SDF format. These structures were then processed and converted to PDB format using Discovery Studio in preparation for molecular docking. Molecular docking analysis Molecular docking studies were carried out using AutoDock Tools version 4.2. The prepared protein and ligand files were imported into their respective docking panels. The binding site for each target was defined using a grid box, with center coordinates and dimensions as summarized in Table 1. For each protein-ligand complex, the pose with the most favorable binding energy (kcal/mol) was selected for further interaction analysis. A detailed assessment of the resulting binding modes was performed to characterize the stability of the complexes. This included an analysis of hydrogen bonding, hydrophobic contacts, and π-interactions. These interactions are summarized in Table 1. Table 1Grid center, dimensions of each target proteins and the amino acid residue present at the active site.Protein targetsCyclophilin DUbiquinol-cytochrome c reductase (bc1 complex)Keap1-Nrf2Mn-SODGrid centersx = 17.8406y = 13.2515z = 6.7398x = 231.7819y = 277.2140z = 248.8771x = -15.2836y = -24.9309z = -14.6065x = 50.8767y = 23.9287z = 91.2557Dimension of the grid boxx = 25.0y = 26.8217z = 23.8816x = 23.0094y = 21.0276z = 30.7334x = 25.0y = 30.4297z = 25.0x = 22.8556y = 22.9487z = 25.0Amino acid at the active sitesAsn102, Gly109Thr107, Ala101, Ala103, Gln111, Gly72, Gln63, Phe113, Phe60, Met61, His126.Asn206, Ser205, Trp31, Arg100, Gly34, His97, Leu197, Ile98, Leu301, Phe90Lys62, His47,Tyr51, Gly29,His27, Phe5,Leu2, Cys44,Cys28, Ala17,Phe98, Ala18.His26, His74,His163, Tyr34and Asp159 Grid center, dimensions of each target proteins and the amino acid residue present at the active site. x = 17.8406 y = 13.2515 z = 6.7398 x = 231.7819 y = 277.2140 z = 248.8771 x = -15.2836 y = -24.9309 z = -14.6065 x = 50.8767 y = 23.9287 z = 91.2557 x = 25.0 y = 26.8217 z = 23.8816 x = 23.0094 y = 21.0276 z = 30.7334 x = 25.0 y = 30.4297 z = 25.0 x = 22.8556 y = 22.9487 z = 25.0 Lys62, His47, Tyr51, Gly29, His27, Phe5, Leu2, Cys44, Cys28, Ala17, Phe98, Ala18. His26, His74, His163, Tyr34 and Asp159 Statistical analysis Data analysis was conducted using Student’s t-test via GraphPad Prism version 8.0.2 (GraphPad Software, Inc., United States). The significance was considered when P < 0.05(*), P < 0.01(**), P < 0.001(***). Results Phytochemicals of EEP Extraction yield, polyphenols, flavonoids, and tannins contents The extraction yield of propolis, polyphenols, Flavonoids, and tannin contents are illustrated in Table 1 S (in supplementary material). The results indicate that EEP presents an extraction yield of 45.25% and contains high concentrations of phenolic compounds, 320.5± 9.15 mg GAE/g of extract, and TFC is equal to 182.8 ± 1.65 mg QE/g. Propolis tannin quantification has rarely been discussed in published research. Mayworm and collaborators41 reported condensed tannin contents ranging from 0.6 to 4.1% in Brazilian propolis, values that are markedly higher than those observed in the present study (0.48%). In contrast, the level of hydrolysable tannins recorded in our samples was relatively elevated, reaching 8.4%. GC-MS analysis Results deciphered the presence of flavonoids in EEP; naringenin as the major constituent with 17.48%, dihydrochrysin 15.62%, pinostrobin chalcone 3.43%, 6-methyltectochrysin 2.97%, phenolic acids like hydroxycaffeic acid 1.36%, terpenes like (E)-methyl communate (4.34%), β-pinene, 3-(acetylmethyl)- (8.23%), and totarol (5.78%), fatty acids and derivatives (palmitic acid methyl ester, palmitic acid, and oleic acid methyl ester). Our study revealed a new component in propolis: N-(tert-Butoxycarbonyl)-3-(4-methoxybenzylthio) alanine (14.96%) (Fig. 1; Table 2). Chromatogram of GC-MS analysis of EEP (Ethanolic extract of propolis). Table 2GC-MS analysis of EEP.PeaknumberRetention time tr(mn)CompoundsChemical formulaArea (%)m/z1234567891011121314151617181920212223242526276.4239.3429.75911.26212.24913.00015.63016.96818.07818.63218.87019.12620.28220.46621.21322.14923.07923.47523.69323.94624.09624.28125.22925.55326.38128.99431.619CedrenolPalmitic acid, methyl esterPalmitic acidSclareolOleic acid, methyl ester1-Undecanol3(Z)-Cembrene ATotarol4-Isopropylidene-7-methyl-6-methylene-2-octenoic acid, methyl ester1,3-bis(2-cyclopropyl-2-methylcyclopropyl) but-2-en-1-onePinostrobin chalcone(E)-Methyl communatea-Hydroxycaffeic acidβ-Pinene, 3-(acetylmethyl)-PinocembrinBenzoic acid, 4-(4-butylcyclohexyl)-, 4-butoxy-2,3-dicyanophenyl esterCembrene CTectochrysinDihydroagathic acid1,2-Benzenedicarboxylic acid, diisooctyl esterTridecanol, 2-ethyl-2-methyl-N-(tert-Butoxycarbonyl) -3-(4-methoxybenzylthio) alanineMegastigma-3,7(E),9-trieneNaringenin2,3-bis(1-methylcyclopropyl) cycloprop-2-en-1-oneTriacontane, 11,20-didecyl-Oxalic acid, allyl pentadecyl esterC15H24OC17H34O2 C16H32O2C20H36 O2C19H36O2C11H24OC20H32C20H30O C14H22O2C18H26OC16H14O4C21H32O2C9H10O5C13H20OC15H12O4C29H34N2O3C20H32C16H12O4C20H32O4C24H38O4C16H34OC16H23NO5SC13H20C15H12O5C11H14OC50H102C20H36O40.650.641.221.120.550.726.365.780.341.953.434.341.368.2315.620.434.372.973.611.170.5114.960.5917.480.730.320.3395.1074.0573.0581.1069.1069.1081.05271.30119.1081.10193.0579.10180.00121.10134.10256.10215.1093.05268.20121.10149.0557.05121.1067.00153.05153.10255.10EEP, ethanolic extract of propolis GC-MS analysis of EEP. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 6.423 9.342 9.759 11.262 12.249 13.000 15.630 16.968 18.078 18.632 18.870 19.126 20.282 20.466 21.213 22.149 23.079 23.475 23.693 23.946 24.096 24.281 25.229 25.553 26.381 28.994 31.619 Cedrenol Palmitic acid, methyl ester Palmitic acid Sclareol Oleic acid, methyl ester 1-Undecanol 3(Z)-Cembrene A Totarol 4-Isopropylidene-7-methyl-6-methylene-2-octenoic acid, methyl ester 1,3-bis(2-cyclopropyl-2-methylcyclopropyl) but-2-en-1-one Pinostrobin chalcone (E)-Methyl communate a-Hydroxycaffeic acid β-Pinene, 3-(acetylmethyl)- Pinocembrin Benzoic acid, 4-(4-butylcyclohexyl)-, 4-butoxy-2,3-dicyanophenyl ester Cembrene C Tectochrysin Dihydroagathic acid 1,2-Benzenedicarboxylic acid, diisooctyl ester Tridecanol, 2-ethyl-2-methyl- N-(tert-Butoxycarbonyl) -3-(4-methoxybenzylthio) alanine Megastigma-3,7(E),9-triene Naringenin 2,3-bis(1-methylcyclopropyl) cycloprop-2-en-1-one Triacontane, 11,20-didecyl- Oxalic acid, allyl pentadecyl ester C15H24O C17H34O2 C16H32O2 C20H36 O2 C19H36O2 C11H24O C20H32 C20H30O C14H22O2 C18H26O C16H14O4 C21H32O2 C9H10O5 C13H20O C15H12O4 C29H34N2O3 C20H32 C16H12O4 C20H32O4 C24H38O4 C16H34O C16H23NO5S C13H20 C15H12O5 C11H14O C50H102 C20H36O4 0.65 0.64 1.22 1.12 0.55 0.72 6.36 5.78 0.34 1.95 3.43 4.34 1.36 8.23 15.62 0.43 4.37 2.97 3.61 1.17 0.51 14.96 0.59 17.48 0.73 0.32 0.33 95.10 74.05 73.05 81.10 69.10 69.10 81.05 271.30 119.10 81.10 193.05 79.10 180.00 121.10 134.10 256.10 215.10 93.05 268.20 121.10 149.05 57.05 121.10 67.00 153.05 153.10 255.10 EEP, ethanolic extract of propolis Antioxidant activity of EEP In order to assess the antioxidant potential of propolis extract, scavenging superoxide anion radical, DPPH, H2O2, and FRAP assays were performed. EEP reduced DPPH proportionally to the concentration (Fig. 2A1). The IC50 of propolis is 26.90 ± 2.95 µg/mL against 47.35 ± 2.95 µg/mL with gallic acid (Fig. 2A2). EEP is more effective than gallic acid. EEP had a higher neutralizing ability, which is intrinsically associated with the higher level of flavonoids. The antioxidant effects of EEP were also assessed by its ability of reducing O2- radical. EEP presented a strong reduction of superoxide anion radical (Fig. 2B1), with an IC50 of 20.31 ± 2.05 µg/mL against 40.25 ± 1.75 µg/mL obtained with gallic acid (Fig. 2B2). Antioxidant activity of EEP, against ( A1) (DPPH free radical), (B1) (O2− radical), (C1) (H2O2), (D1) (Reducing power) of EEP (Ethanolic Extract of Propolis) and gallic acid and the values of EC50 (A2, B2, C2, D2) respectively. Statistical analysis was performed using the t-test, with Statistical analysis was performed using the t-test, with: P > 0.05 (ns), P < 0.05(*), EEP (Ethanolic extract of propolis). The superoxide anion radical can initiate oxidative reactions that lead to the formation of hydrogen peroxide and hydroxyl radicals. EEP presents a reducing capacity of hydrogen peroxide better than that of gallic acid, with EC50 of 15.45 ± 1.55 and 26.2 ± 2.52 µg/mL, respectively. At 200 µg/mL, the hydrogen peroxide scavenging activity of EEP is equal to 97 ± 3.91% against 82 ± 0.63% obtained with gallic acid (Fig. 2C1,C2). The presence of phenolic compounds capable of donating electrons to H₂O₂ explains the extract’s ability to neutralize H₂O₂. The reducing capacity of a compound may serve as a significant indicator of its potential antioxidant activity. The electron-donating ability of EEP and thus their potential role in the reduction of the oxidized intermediates of the lipid peroxidation process were determined. EEP has an excellent reducing capacity. it showed a higher effect in comparison with gallic acid used as a standard (Fig. 2D1). The EC50s were respectively 15.22 ± 1.25 µg/mL and 79.03 ± 0.573 µg/mL (Fig. 2D2). In vivo sub-chronic toxicity of EEP Behavioral observations According to our research, treated rats did not show any behavioral abnormalities from EEP throughout the study. Furthermore, during the thirty-day trials, no deaths were reported, and no toxicological symptoms were observed in the treated animals at 100 mg/kg. Effect on body and relative organ weights (ROW) Our findings demonstrated that treatment with EEP at a dose of 100 mg/kg led to a significant increase in body weight, while no notable changes were observed in the relative weights of the liver or kidneys in the treated rats compared to the control group, as detailed in Table 3. Table 3Body weight and relative organ weights of rats treated with EEP (100 mg/kg) and the control group. Data represent the mean ± SEM (n = 10).Body weightBW (g)Relative liver weights(RLW)Relative renal weights(RRW)Control180.5 ± 6.114.71 ± 0.530.81 ± 0.04EEP (100 mg/kg)225 ± 8.53 *4.91 ± 0.23 ns0.78 ± 0.11 nsStatistical analysis was performed using the t-test, with (ns) indicating no significant difference and (*) marking significant differences at p < 0.05. Body weight and relative organ weights of rats treated with EEP (100 mg/kg) and the control group. Data represent the mean ± SEM (n = 10). Statistical analysis was performed using the t-test, with (ns) indicating no significant difference and (*) marking significant differences at p < 0.05. Liver and kidney function tests after administration of EEP The impact of propolis on serum biochemical parameters, including ASAT, ALAT, LDH activities, protein content, creatinine, uric acid, and blood urea nitrogen (BUN), is summarized in Table 4. The findings reveal no significant changes in serum LDH activity and protein levels in rats following 30 days of EEP treatment compared to the control group (p > 0.05). However, ASAT and ALAT activities were notably reduced by 28.43% and 17.41%, respectively, relative to controls. Table 4Effect of EEP on the activities of alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), lactate dehydrogenase (LDH), and protein content, Creatinine and blood area (BUR) in rats’ serum.ASAT(IU/mL)ALAT(IU/mL)LDH(IU/mL)Proteins(mg/mL)Creatinine (mg/dL)BUR(mg/mL)Control0.211 ± 6.610.113 ± 0.091.121 ± 0.02183.3 ± 1.550.61 ± 0.0515.25 ± 1.02EEP (100 mg/kg) 0.151 ± 2.54 * 0.093 ± 0.011* 1.098 ± 0.025 ns 92.4 ± 9.05 ns 0.58 ± 0.02 ns15.12 ± 1.25 nsStatistical analysis was performed using the t-test, with Statistical analysis was performed using the t-test, with: P > 0.05 (ns), P < 0.05(*). EEP, ethanolic extract of propolis. Effect of EEP on the activities of alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), lactate dehydrogenase (LDH), and protein content, Creatinine and blood area (BUR) in rats’ serum. Statistical analysis was performed using the t-test, with Statistical analysis was performed using the t-test, with: P > 0.05 (ns), P < 0.05(*). EEP, ethanolic extract of propolis. Effect on mitochondrial superoxide anion and permeability transition pore (mPTP) Superoxide anion production by mitochondrial complex III was measured to assess the antioxidant or prooxidant effects of propolis extracts in liver and kidney mitochondria. The results demonstrated that EEP treatment reduced superoxide generation by 65.75% in liver mitochondria and 70.45% in kidney mitochondria, as illustrated in Fig. 3a. These findings highlight the potent antioxidant activity of propolis extracts against mitochondrial superoxide anion production. Additionally, mitochondrial swelling (Fig. 3b), showed a significant reduction in rats treated with EEP at 100 mg/kg compared to the control group. Specifically, mitochondrial swelling decreased by approximately 32.75% in the liver and 50.95% in the kidney, corresponding to inhibition rates of 67.25% and 49.05%, respectively). Mitochondrial Superoxide anion production (a) and mitochondrial Swelling (b) in the rat liver and kidney of rats orally treated with EEP (Ethanolic Extract of Propolis) at 100 mg/kg/day for 30 days. Student’s t-test: P < 0.05(*), P < 0.01(**), P < 0.001(***). EEP, ethanolic extract of propolis. Effect on mitochondrial and cellular lipid peroxidation and GSH content We registered a highly significant increase in liver and kidney GSH in rats receiving EEP versus healthy animals, compared to the control group, and a highly significant reduction (p < 0.001) in cytosolic and mitochondrial MDA rates after one month of treatment by EEP (100 mg/kg/day) compared to the control (Fig. 4). Mitochondrial and cytosolic MDA and GSH in liver (A, B, C) and Kidney (D, E, F) from rats treated with EEP (Ethanolic Extrac of Propolis) at 100 mg/kg/day for 30 days. Student’s t-test: P < 0.05(*), P < 0.01(**), P < 0.001(***). EEP, ethanolic extract of propolis. Effect on mitochondrial and cytosolic antioxidant enzymes (CAT, SOD) activities Mitochondrial and cytosolic CAT and SOD activities increases significantly in EEP-treated rats compared to control (Table 5)‏. Cytosolic SOD activity was increased by 124.26% compared to the untreated group. Table 5Mitochondrial and cytosolic SOD and CAT activities in the liver and the kidney of rats treated with EEP at 100 mg/kg/day for 30 days.LiverKidneyControlEEP (100 mg/kg)ControlEEP (100 mg/kg)Cyt. SOD (UI/g Pr)3.03 ± 0.823.92 ± 1.011 **2.13 ± 0.723.21 ± 1.13 ***Mit. SOD (UI/g Pr)1.62 ± 0.983.23 ± 1.102 ***1.04 ± 0.192.21 ± 0.32 ***Cyt. CAT (UI/g Pr)4.36 ± 0.314.76 ± 1.92 *2.35 ± 0.423.05 ± 0.95 ***Mit. CAT (UI/g Pr)2.65 ± 0.433.64 ± 0.76 ***1.75 ± 0.232.55 ± 0.35 ***Statistical analysis was performed using the t-test, with Statistical analysis was performed using the t-test, with: P < 0.05(*), P < 0.01(**), P < 0.001(***). EEP, ethanolic extract of propolis. Mitochondrial and cytosolic SOD and CAT activities in the liver and the kidney of rats treated with EEP at 100 mg/kg/day for 30 days. Statistical analysis was performed using the t-test, with Statistical analysis was performed using the t-test, with: P < 0.05(*), P < 0.01(**), P < 0.001(***). EEP, ethanolic extract of propolis. Hepato-renal histopathological study The histological evaluation of liver and kidney tissues from both experimental groups is illustrated in Figs. 5 and 6, respectively. Microscopic examination of liver sections from control animals revealed a well-preserved architecture (Fig. 5A,C), free from vascular alterations or inflammatory cell infiltration. Similarly, rats receiving oral doses of EEP (100 mg/kg body weight) for one month exhibited hepatic structures comparable to those of the control group. Detailed observation confirmed a normal lobular organization, with the central vein clearly positioned at the center of each lobule (Fig. 5B,D). Hepatocytes appeared intact, showing a granular, intensely eosinophilic cytoplasm with distinct nuclei. Hepatic sinusoids were regularly arranged between the hepatocyte cords, while the portal triad structures maintained their typical organization and were surrounded by connective tissue. Examination of rat liver’s histopathology (H&E). (A) Control group (×100), (B) EEP-treated group (100 mg/kg, ×100), (C) Control group (×400), (D) EEP-treated group (100 mg/kg, ×400). CV, central vein; PV, portal vein; EEP, ethanolic extract of propolis. Examination of the rat kidney’s histopathology (H&E). (A) Control group (×100), (B) EEP-treated group (100 mg/kg, ×100), (C) Control group (×400), (D) EEP-treated group (100 mg/kg, ×400). Glomeruli (black arrow), renal tubules (red arrow). EEP, ethanolic extract of propolis. Light microscopic examinations exhibited normal renal corpuscles and tubules in the control group (Fig. 6A,C) and EEP-treated group (Fig. 6B,D). In the control, the kidney tissue revealed a normal and healthy architecture (A) with preserved glomeruli (black arrow) and renal tubules (red arrow), with the absence of congestion and interstitial inflammation. In the case of treatment with EEP (Fig. 6B,D), the renal tissue presents a normal tissue appearance, with preservation of the glomerular spaces (black arrow). The renal tubules (red arrow) show a well-preserved morphology; no abnormality was detected. The renal tissue is comparable to that of the control. It appeared structurally and functionally normal. There is no dilatation nor congestion of the peritubular vessels and renal corpuscles in EEP-treated rats. In silico study Drug likeness of the EEP compounds Table 2S (in supplementary material) presents the drug-likeness profiles of the 27 evaluated compounds, assessed according to Lipinski’s, Muegge’s, Ghose’s, Veber’s, and Egan’s rules. In addition, the bioavailability score of each compound was determined (Fig. S2). Effect of EEP compounds on protein targets: Keap1-Nrf2, bc1 complex, Cyclophilin D and Mn-SOD The ranking of protein–ligand complexes was performed based on their docking scores (binding energies). The top nine compounds were docked against four protein targets, with five compounds demonstrating strong binding affinities, as detailed in Table 6. The chemical structures of these five EEP-derived compounds exhibiting favorable binding interactions with the target proteins are illustrated in Fig. 7. Table 6Binding energy of drug-like compounds docked against Cyclophilin D, bc1 complex, Keap1-Nrf2, and Mn-SOD.LigandBinding energy (kcal/mol)Cyclophilin DKeap1-Nrf2Mn-SODUbiquinol-cytochrome c reductase (bc1 complex)Cyclosporine_A*− 5.7–––Oltipraz*–-6.0––Deferoxamine*––− 5.4–Actinomycin D*–––− 2.7Naringenin− 7.5− 8.3− 6.2− 8.9Pinocembrin− 7.5− 8.4− 6.4− 9.4Tectochrysin− 7.5− 8.2− 6.6− 8.93(Z)-Cembrene− 6.4− 8.4− 5.8− 9.1Totarol− 6.4− 7.8− 5.9− 9.6*Control drugs. Binding energy of drug-like compounds docked against Cyclophilin D, bc1 complex, Keap1-Nrf2, and Mn-SOD. *Control drugs. Chemical structure of five EEP- compounds that presented good binding affinity against target proteins (Cyclophilin D, Keap1-Nrf2, Mn-SOD, bc1 complex). Molecular interaction and binding cavity analysis The binding modes and molecular interactions provide critical insight into the structural stability and affinity of the top-ranked compounds within the active sites of the target proteins. The 2D interaction fingerprints and 3D surface visualizations of these complexes are presented in Fig. 8. Molecular interaction and surface analysis of lead compounds. The 2D interaction plots and corresponding 3D surface representations illustrate the binding orientation and cavity occupancy for: (A) Cyclophilin D with Naringenin, (B) Mn-SOD with Tectochrysin, (C) Keap1-Nrf2 with Pinocembrin, and (D) BC1 complex with Totarol. Naringenin demonstrated a superior binding mode within the Cyclophilin D cavity. As shown in the surface representation, the molecule occupies the primary binding pocket, stabilized by a network of conventional hydrogen bonds with the side chains of Ala101, Gln111, and Ser110. The 3D analysis confirms that Naringenin sits flush within the catalytic site, suggesting a high degree of conformational stability. The molecular interactions for Tectochrysin within the active site of Manganese-Superoxide Dismutase (Mn-SOD) were predominantly hydrogen bonds and π-interactions. Specifically, Tectochrysin established stable hydrogen bonds with the side chains of Tyr166 and His163, reinforced by a specialized π-cation interaction with His30. The surface mapping illustrates a high degree of complementarity, where the compound fits precisely into the ROS-scavenging pocket. Pinocembrin demonstrated superior docking scores and binding stability compared to other propolis-derived constituents when targeted against the Keap1-Nrf2 interface. The interaction analysis reveals that Pinocembrin establishes a robust hydrogen bonding network with Val463, Ile416, and Leu557. The 3D surface model highlights that Pinocembrin binds deeply within the Kelch domain cavity, the critical site where endogenous Nrf2 ligands typically interact. For the mitochondrial BC1 complex (cytochrome bc1), Totarol was identified as the lead interactor. Unlike the other targets, the binding within this non-polar cavity is primarily governed by hydrophobic forces, including π-sigma, π-alkyl, and π-π stacked interactions with Phe95, Phe276, and Leu332. The surface visualization depicts Totarol effectively occupying the ubiquinol-binding pocket, aligning with the lipophilic nature of this transmembrane target. ADME and toxicity prediction The ADMET (absorption, distribution, metabolism, excretion, and toxicity) results, presented in Table 3S, were evaluated using the ADMET-AI web server (https://admet.ai.greenstonebio.com)42. Assessment of ADMET properties is essential during the early stages of drug discovery and development, as promising drug candidates must demonstrate not only potent activity against their therapeutic targets but also favorable ADMET profiles at the intended therapeutic doses43. A summary of the ADMET prediction outcomes is provided in Table 3S. All five compounds achieved a Human Intestinal Absorption score of 1.00, likely reflecting high membrane permeability. However, their low aqueous solubility (− 3.72 to − 6.22 log mol/L) classifies them as Biopharmaceutics Classification System (BCS) Class II candidates, meaning dissolution rate rather than permeability is the primary limit to absorption. Naringenin is least affected by these constraints, whereas 3(Z)-Cembrene A and Totarol are most impacted. Furthermore, Tectochrysin’s strong P-glycoprotein inhibition (0.82) suggests potential drug-drug interaction concerns through the modulation of efflux transporters. Once absorbed, distribution is governed by high plasma protein binding (86.68–100%). While Naringenin maintains a free drug fraction of approximately 13%, the other leads show near-complete binding, potentially limiting their pharmacological availability. Volume of distribution (VDss) values reveal a stark contrast: 3(Z)-Cembrene A (9.16 L/kg) and Totarol (7.16 L/kg) show extensive tissue sequestration consistent with high lipophilicity, whereas Tectochrysin’s VDss of 0.00 L/kg indicates extreme plasma confinement rather than a literal absence of volume. Regarding metabolism and excretion, the metabolic profiles show that Tectochrysin, Naringenin, and Pinocembrin are potent CYP1A2 inhibitors, while Totarol and 3(Z)-Cembrene A are susceptible to extensive CYP3A4-mediated first-pass metabolism. For excretion, this susceptibility, combined with high hepatocyte clearance (105–118 µL/min/10⁶ cells) and negligible predicted half-lives for four of the leads (only 3(Z)-Cembrene A shows a measurable half-life of 5.55 h), suggests poor metabolic stability and rapid elimination, necessitating structural optimization to improve systemic residency. The identified compounds, notably naringenin, pinocembrin, and tectochrysin, may act as inhibitors of certain CYP isoenzymes (in particular CYP2C9, CYP1A2, and possibly CYP3A4) and, for some of them, as substrates of CYP2C9 and CYP2D6. These properties are likely to alter the metabolism of co-administered drugs that depend on these isoenzymes, with a risk of increased systemic exposure and adverse effects for drugs with a narrow therapeutic index. Conversely, concomitant induction or inhibition of these CYPs may also influence the clearance of, and response to, the compounds themselves, thereby introducing interindividual variability. Thus, the use of the extract, especially at high doses or over long-term regimens, should be considered with caution in patients treated with CYP2C9 or CYP2D6 substrates, pending dedicated pharmacokinetic and herb–drug interaction studies. Safety profiles are generally acceptable; however, elevated drug-induced liver injury (DILI) probabilities for Tectochrysin (0.85) and Naringenin (0.63) warrant hepatic monitoring. Additionally, moderate hERG blocking probabilities for Tectochrysin and Totarol indicate potential cardiac safety risks. In summary, overall efficacy is determined by the interplay of bioavailability, distribution, and clearance. Naringenin emerges as the most promising candidate due to its superior solubility and free drug fraction. Conversely, 3(Z)-Cembrene A suffers three sequential losses (poor dissolution, high first-pass metabolism, and complete protein binding), meaning its circulating free drug concentration would be minimal despite high HIA scores. Such leads would require advanced formulation or structural modification to achieve therapeutic concentrations. The synergistic interactions among propolis’s molecules are vital for boosting its overall therapeutic efficacy while decreasing the toxicity of its individual components. Our in vivo study has shown promising results regarding the safety profile of propolis. Cellular and blood tests revealed normal levels of liver and kidney function markers, suggesting that propolis does not induce any toxicity in these vital organs. This supports the conclusion that propolis is a safe natural product for potential therapeutic use. It is worth mentioning also that drug design allows for the development of safer and more effective molecules by improving their structure and biological properties to reduce toxicity, while enhancing their therapeutic benefits. Discussion The safety of Algerian propolis is very important in relation to its large medicinal use. Such evaluations are crucial to mitigate any potential health risks associated with its extensive application in traditional medicine. In our study, the extraction yield of Algerian propolis was roughly equivalent to 45.25% (wt/wt), which falls within the range of values previously documented in the published literature. For instance, in a study conducted by Nieva et al., the reported yields from Argentine propolis extract fell between 31 and 65%44. Additionally, our result corroborates the previously obtained (41–60%) from the ethanolic extract of Propolis gathered from Brazil. According to Tran et al., the extraction yield of Australian propolis spanned from 19 to 69%45. The differences in yields might result from suboptimal beekeeping practices. Moreover, factors such as the extraction technique, choice of solvent, duration of extraction, and temperature can significantly influence the overall yield46. The large discrepancies in the yield of extraction, notwithstanding the employment of uniform extraction methodology, provide evidence for the heterogeneous nature of propolis composition, which is typically influenced by the geographical location’s climate and other environmental parameters12. A substantial content of polyphenols, coupled with robust antioxidant properties, was registered in EEP after the preliminary chemical screening and a panel of in vitro assays. Interestingly, these findings were supported by GC-MS profiling, which deciphered a range of flavonoids (pinostrobin chalcone, tectochrysin, naringenin, and chrysin), phenolic acids, terpenes and fatty acids, and derivatives. Effectively, some analogies in the qualitative composition of Algerian and Turkish propolis47, as well as Algerian and propolis originating from America and the Mediterranean basin48. Our results partially agree with other studies that have reported the presence of gallic acid, caffeic, chlorogenic, and coumaric acid as the most abundant compounds in extracts of propolis growing in Algeria49. Pinocembrin and chrysin have been identified as crucial contributors to the insightful antioxidant activity of propolis, working in synergy with other compounds to enhance the desired effect12. The ability to neutralize free radicals was empirically verified in our research. Surprisingly, the destruction of O2- and DPPH radicals by EEP was of greater potency than that of gallic acid, as evidenced by its lower IC50 equivalent to 20.31 ± 2.05 µg/mL and 13.80 ± 2.51 µg/mL, respectively. This study’s outcome corroborates the trend observed in propolis samples harvested from the Czech Republic, where propolis effectively removed the DPPH with an IC50 value of 27.72 µg/mL50. Propolis gathered from Ireland exhibited an excellent antioxidant activity by destroying the DPPH radical with an IC50 value of 26.45 µg/mL. The pronounced antioxidant efficacy of EEP is robustly associated with phenolic and flavonoid compounds unveiled by GC-MS analysis; most of them have been proven to have a robust antioxidant performance as indicated by published literature data. The most plausible explanation is that EEP’s bioactive molecules interact synergistically by transforming free radicals into more stable derivatives and providing them with an electron to halt the propagation of the uncontrolled radical chain reactions51. As part of the evaluation of the toxicity of propolis, we evaluated its effect on serum parameters and the mitochondrial and cytosolic prooxidant-antioxidant balance in the liver and kidney as the main target organs. Results showed that EEP is a natural renal and liver-protecting substance that reduces levels of liver enzymes ASAT and ALAT. It has no effect on LDH, blood urea, and creatinine. This is thought to occur due to its bioactive ingredients, like flavonoids and phenolic compounds. They act as antioxidants that eliminate the free radicals and prevent oxidative damage to the liver52. EEP’s anti-inflammatory properties reduce the production of inflammatory cytokines like TNF-α and IL-6, preventing cell damage caused by inflammation53. In addition, propolis plays a role in stabilizing hepatocyte membranes to inhibit enzyme leakages into the blood flow54. Together, these effects afford broad protection of the liver and kidney by alleviating oxidative stress and inflammation and preserving the integrity of liver and renal cells. The in vivo study showed that Algerian propolis improves liver and kidney antioxidant-prooxidant balance in rats. As a result, EEP significantly reduced the production of O2- by mitochondrial complex III, which is responsible for most of the ROS formation at the electron transport chain. By the way, the autooxidation of ubisemiquinone emerging in the Q cycle of complex III supports the generation of O2-55. The effect of EEP may be attributed to a direct scavenging action of superoxide anion or the inhibition of its generation by partially inhibiting the mitochondrial complex III. Our results correlate perfectly with those of other researchers34. As mentioned in the phytochemical section, an array of bioactive molecules such as flavonoids, aromatic acids, is frequently available in propolis; they usually interact synergistically, potentiating their biological activity toward various toxic xenobiotics56. In this study, the supplementation by propolis extract for 30 days has resulted in a highly significant increase in renal and liver GSH rates compared to those obtained with controls. This rise in GSH rate is likely stemming from the stimulation of its synthesis and/or its regeneration. This could be due to the ability of propolis’s flavonoids to quench highly reactive species, where the free radicals will be neutralized by flavonoids, maintaining GSH levels57. Our results unequivocally show that EEP supplementation at 100 mg/kg for 30 days significantly suppressed mitochondrial and cellular lipid peroxidation. This treatment notably decreased MDA levels in both the liver and kidneys. Free radicals are adequately mopped up by polyphenols, thus safeguarding lipids, proteins, and DNA from oxidative injury. Extensive research has deeply explored the prophylactic properties of phenolic compounds against lipid oxidation. Osada and Sugano demonstrated that polyphenols effectively prevent the oxidation of cholesterol and linoleic acid by scavenging free radicals58. Earlier research’s findings proved that lipid oxidation was effectively inhibited by propolis in renal and liver tissues59. Moreover, phenolic compounds interrupt the continuous generation of free radicals and quench free radical reactions by sequestering metal ions60. Propolis supplementation led to an enhancement in the activity levels of both mitochondrial and cytosolic CAT as well as SOD. These are congruent with those reported by other researchers57. Our study demonstrated that EEP-treated rats show normal liver histological structure, normal hepatocytes, sinusoids, and portal area, and there is preservation of kidney structure after a supplementation of 100 mg/kg for 30 days. Propolis has been shown to improve liver histological changes in various studies: Adel Mohamed Mahmoud et al. found that propolis at 100 mg/kg for 28 days reduced histopathological degenerative effects in the liver after treatment with cisplatin59. Similarly, Elakabawy et al.61 demonstrated that propolis significantly enhanced kidney performance and oxidative stress biomarkers. It also apparently reduced histopathological changes induced by adenine in rats. Multiple lines of evidence support propolis’s effectiveness on liver histology. Moreover, administering propolis has been proven to successfully mitigate the negative consequences of anti-cancer therapy, such as Doxorubicin30, which collectively suggests that propolis has hepato- and nephroprotective effects and can improve liver and renal histological changes in various toxicological conditions15. The in-silico data shed light on the possible therapeutic pathways by which EEP compounds might regulate mitochondrial homeostasis, oxidative stress, and cell survival pathways, offering possible treatments for diseases associated with mitochondrial dysfunction and oxidative damage. The molecular interactions of Naringenin, Pinocembrin, Tectochrysin, and Cyclosporine A with Cyclophilin D primarily involved hydrogen bonds and π- interactions at the enzyme’s binding sites. These interactions highlight the key role of hydrogen bonds in stabilizing the binding of these compounds to Cyclophilin D. These findings are consistent with recent reports, where the inhibition of Cyclophilin D was shown to potentially prevent mitochondrial pore opening and subsequent cell death, providing a promising therapeutic pathway for mitochondrial-related diseases62. Thus, the strong binding affinity between EEP compounds and Cyclophilin D offers a compelling rationale for their potential use in treating diseases characterized by mitochondrial damage. Additionally, molecular docking analysis revealed that some EEP compounds can bind effectively to the bc1 complex, enhancing its stability and potentially improving mitochondrial respiration. The molecular interactions of totarol, pinocembrin, 3(Z)-cembrene A, and actinomycin D with the cytochrome bc1 complex are primarily involved in Van der Waals forces, hydrogen bonds, and π- interactions. These interactions highlight varying binding patterns among the compounds, with some relying more on non-covalent forces, while others, like actinomycin D, establish stronger hydrogen bonding. Our results align with recent studies showing that small molecules with antioxidant properties can protect mitochondrial complexes from oxidative damage and enhance electron transport chain function. The study by Li et al.44 demonstrated that plant-derived compounds can significantly improve mitochondrial bioenergetics by stabilizing electron transport complexes, which are often compromised under oxidative stress. Therefore, our findings support the notion that EEP compounds could improve mitochondrial efficiency and energy production63, which is particularly relevant for diseases associated with mitochondrial dysfunction29. According to the docking simulations, EEP compounds engage with Keap1’s Kelch domain, causing Nrf2 activation and the disruption of the Keap1-Nrf2 complex. The molecular interactions of naringenin, pinocembrin, 3(Z)-cembrene A, and oltipraz with the Keap1-Nrf2 complex were mainly driven by hydrogen bonds and π- interactions within the enzyme’s active site. These interactions highlight the varying binding profiles of the compounds, with some showing stronger interactions than others, which may have implications for their potential effects on the Keap1-Nrf2 pathway. Recent studies have demonstrated that small compounds, especially flavonoids, can activate the Keap1-Nrf2 pathway and provide cellular protection against oxidative stress, which lends credence to our findings. In chronic diseases like cancer, neurological diseases, and cardiovascular diseases, Nrf2 activation is very important for reducing oxidative damage. EEP chemicals may provide a potent way to shield cells from oxidative damage and enhance cellular homeostasis by triggering Nrf2 activity64. Moreover, EEP compounds have a substantial binding affinity for the Mn-SOD active site, forming important interactions at residues such as Tyr-34 and His-63 that are critical for the catalytic. activity of the enzyme65. Our study’s binding affinity indicates that EEP chemicals may boost Mn-SOD activity, strengthening mitochondrial antioxidant defenses. The interactions between naringenin, pinocembrin, tectochrysin, and deferoxamine with Mn-SOD primarily involve hydrogen bonds and π- interactions with key amino acid residues in the enzyme’s active site (as depicted in Fig. 2A-D). These interactions underscore the strong binding affinity of these compounds for Mn-SOD, suggesting their potential in modulating the enzyme’s activity and contributing to protective effects, particularly against oxidative stress. ADMET profiling confirmed that the selected compounds demonstrated favorable absorption, distribution, and metabolic profiles. All compounds were predicted to permeate Caco-2 cells for intestinal absorption. Tectochrysin, 3(Z)-cembrene A, and totarol inhibited p-glycoprotein, but none were substrates for it. They showed a high volume of distribution (VD), with 3(Z)-cembrene A having the highest value, indicating effective tissue distribution. In terms of metabolism, several compounds were predicted to inhibit Cytochrome P450 enzymes. Naringenin, pinocembrin, and tectochrysin inhibited multiple P450 isoforms, while 3(Z)-cembrene A and totarol were substrates for certain enzymes. For excretion, naringenin had a high clearance. rate, while pinocembrin and 3(Z)-cembrene A had moderate clearance, and tectochrysin had a low clearance rate. All compounds were predicted to have a short half-life, suggesting rapid elimination. The compounds showed promising drug-like properties. Regarding toxicity, all compounds except tectochrysin were non-AMES-toxic, indicating no mutagenic potential. 3(Z)-cembrene A was the only compound predicted to cause hepatotoxicity, while others showed negative results. Specifically, high intestinal permeability and adequate solubility suggest favorable absorption, while strong plasma protein binding may influence distribution and limit free drug availability. Interactions with cytochrome P450 enzymes indicate possible metabolic stability or risk of drug interactions. Additionally, clearance and half-life values will be discussed to better understand excretion patterns. Altogether, these parameters will be linked to the overall bioavailability and pharmacokinetic behavior of the identified compounds66. Concurrently, the ADMET profiling revealed the toxicity of some compounds. The pharmacological efficacy of propolis extract likely derives from a multifactorial synergy between its bioactive constituents, which collectively modulate diverse molecular targets and physiological pathways. Notably, even trace phytochemicals, though present in minimal concentrations, may confer bioactive properties that amplify therapeutic outcomes, as Abd-El-Aziz et al. 67 postulate. Current research suggests these components operate through either independent mechanisms or cooperative interactions, creating a poly-mechanistic framework that complicates the isolation of singular causative agents68. Such synergistic dynamics may further elucidate observed discrepancies between in silico ADMET predictions and empirical in vitro findings. The contradiction in such outcomes is related to the scenario of the synergism existing between different molecules69,70. Researchers have been vividly confirming, supporting, and expanding information about the safe profile of Algerian Propolis extract, reinforcing their potential as safe therapeutic adjuvants71. Numerous studies have focused on the explicit establishment of a mechanism by means of synergy. For instance, it has been detected that a certain combination of molecules in plant infusions can increase bioavailability, improve cell consumption, and modulate the metabolic nerve pathway, leading to more targeted and successful antioxidant and anti-inflammatory curative effects72. For instance, polyphenols in green tea infusions have been developed with a higher antioxidant potential compared to whole intensification73. Conclusion This study provides a comprehensive evaluation of the phytochemical composition, antioxidant capacity, and sub-chronic safety of Algerian propolis ethanolic extract. The extract exhibited high phenolic and flavonoid contents and demonstrated marked antioxidant effects, contributing to the maintenance of redox balance and mitochondrial integrity in vivo. Repeated oral administration at a dose of 100 mg/kg/day for 30 days did not induce adverse biochemical, functional, or histopathological alterations in hepatic or renal tissues, consistent with a sub-chronic toxicity profile according to OECD guidelines. Molecular docking analyses revealed favorable binding interactions of major constituents with redox- and mitochondria-related targets, including Keap1-Nrf2, Cyclophilin D, bc1 complex, and Mn-SOD. In silico pharmacokinetic predictions further supported the favorable safety characteristics of the major identified compounds. Collectively, these findings support the biological safety of Algerian propolis under the tested experimental conditions. However, further studies involving multiple dose levels, longer treatment durations, expanded toxicological evaluations, in vivo pharmacokinetic characterization, and mechanistic validation are required to confirm its safety profile and therapeutic potential. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors gratefully acknowledge the support from the Algerian Ministry of Higher Education and Scientific Research (MESRS, DGRSDT). The study is partially supported via funding from Prince Sattam bin Abdulaziz University, project number PSAU/2026/R/1447. Author contributions W.K.: Writing—review and editing, methodology, validation, and investigation. H.R.: Methodology, validation, resources. S.B.: Writing—review and editing. TVA and HIU: Investigation, methodology, Software, and Writing—original draft. M.L.: Supervision, conceptualization, and Writing—review and editing. R.M.A., V.D.S., S.F.: resources, formal analysis, and fund acquisition. S.H.S.: Writing—review and editing, Validation, resources, formal analysis, and fund acquisition. All authors have read and agreed to the published version of the manuscript. Data availability All experimental data were provided in the manuscript. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Widad Kebsa, Email: w.kebsa@univ-jijel.dz. Sherouk Hussein Sweilam, Email: s.sweilam@psau.edu.sa. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All experimental data were provided in the manuscript.